TCR activation mimics CD127


Journal

Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902

Informations de publication

Date de publication:
17 Apr 2019
Historique:
received: 06 06 2018
accepted: 28 12 2018
entrez: 19 4 2019
pubmed: 19 4 2019
medline: 18 12 2019
Statut: epublish

Résumé

Sepsis is the leading cause of mortality for critically ill patients worldwide. Patients develop T lymphocyte dysfunctions leading to T-cell exhaustion associated with increased risk of death. As interleukin-7 (IL-7) is currently tested in clinical trials to reverse these dysfunctions, it is important to evaluate the expression of its specific CD127 receptor on the T-cell surface of patients with septic shock. Moreover, the CD127 CD127 expression was followed at the protein and mRNA levels in patients with septic shock and healthy volunteers. CD127 In patients, neither CD127 expression nor its corresponding mRNA transcript level was modified compared with normal values. However, the percentage of CD127 The proportion of CD127

Sections du résumé

BACKGROUND BACKGROUND
Sepsis is the leading cause of mortality for critically ill patients worldwide. Patients develop T lymphocyte dysfunctions leading to T-cell exhaustion associated with increased risk of death. As interleukin-7 (IL-7) is currently tested in clinical trials to reverse these dysfunctions, it is important to evaluate the expression of its specific CD127 receptor on the T-cell surface of patients with septic shock. Moreover, the CD127
METHODS METHODS
CD127 expression was followed at the protein and mRNA levels in patients with septic shock and healthy volunteers. CD127
RESULTS RESULTS
In patients, neither CD127 expression nor its corresponding mRNA transcript level was modified compared with normal values. However, the percentage of CD127
CONCLUSIONS CONCLUSIONS
The proportion of CD127

Identifiants

pubmed: 30995946
doi: 10.1186/s13054-018-2305-5
pii: 10.1186/s13054-018-2305-5
pmc: PMC6472012
doi:

Substances chimiques

IL7 protein, human 0
Interleukin-7 0
Interleukin-7 Receptor alpha Subunit 0
PDCD1 protein, human 0
Programmed Cell Death 1 Receptor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

131

Références

Annu Rev Immunol. 2003;21:305-34
pubmed: 12471050
Crit Care Med. 2003 Apr;31(4):1250-6
pubmed: 12682500
Eur J Haematol. 2004 Mar;72(3):203-12
pubmed: 14962239
J Immunol. 2005 Mar 1;174(5):2900-9
pubmed: 15728501
Nat Med. 2006 Oct;12(10):1198-202
pubmed: 16917489
Hepatology. 2006 Nov;44(5):1098-109
pubmed: 17058243
J Virol. 2007 Mar;81(6):2545-53
pubmed: 17182670
J Hosp Infect. 2007 Jun;65 Suppl 2:171-3
pubmed: 17540265
Int J Cancer. 2007 Oct 1;121(7):1512-9
pubmed: 17546596
J Am Coll Surg. 2008 Feb;206(2):335-42
pubmed: 18222389
Intensive Care Med. 2009 Apr;35(4):678-86
pubmed: 18946659
Blood. 2009 Aug 20;114(8):1537-44
pubmed: 19423728
Nat Med. 2009 May;15(5):496-7
pubmed: 19424209
J Immunol. 2010 Apr 1;184(7):3768-79
pubmed: 20200277
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80
pubmed: 20385810
PLoS Pathog. 2010 Jun 10;6(6):e1000947
pubmed: 20548953
Science. 1990 Jun 15;248(4961):1349-56
pubmed: 2113314
J Immunol. 2011 Apr 1;186(7):4200-12
pubmed: 21383243
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
Nat Biotechnol. 2011 Oct 02;29(10):886-91
pubmed: 21964415
Crit Care Med. 2011 Nov;39(11):2425-30
pubmed: 22005222
JAMA. 2011 Dec 21;306(23):2594-605
pubmed: 22187279
Semin Immunol. 2012 Jun;24(3):218-24
pubmed: 22410365
J Infect Dis. 2012 Aug 15;206(4):606-16
pubmed: 22693226
Crit Care. 2012 Jun 28;16(3):R112
pubmed: 22742734
Cytometry B Clin Cytom. 2013 Jan-Feb;84(1):59-62
pubmed: 22987669
J Immunol. 2012 Nov 15;189(10):5073-81
pubmed: 23053510
N Engl J Med. 2013 Aug 29;369(9):840-51
pubmed: 23984731
Nat Rev Immunol. 2013 Dec;13(12):862-74
pubmed: 24232462
Crit Care. 2014 Jan 04;18(1):R3
pubmed: 24387680
Front Immunol. 2013 Dec 19;4:455
pubmed: 24391639
Shock. 2014 Nov;42(5):383-91
pubmed: 25051284
N Engl J Med. 2014 Jul 24;371(4):380-3
pubmed: 25054723
J Immunol Methods. 2014 Dec 15;415:71-9
pubmed: 25450005
Shock. 2015 Jun;43(6):569-75
pubmed: 25692255
Nat Commun. 2015 Mar 26;6:6692
pubmed: 25809635
Nature. 2015 Jul 30;523(7562):612-6
pubmed: 26123020
Cytometry B Clin Cytom. 2016 Jul;90(4):376-86
pubmed: 26130241
Curr Protoc Immunol. 2015 Aug 03;110:6.24.1-18
pubmed: 26237012
JAMA. 2016 Feb 23;315(8):775-87
pubmed: 26903336
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
J Immunol Methods. 2016 Oct;437:43-52
pubmed: 27555239
PLoS One. 2017 Jan 10;12(1):e0169653
pubmed: 28072859
Intensive Care Med. 2017 Jul;43(7):1013-1020
pubmed: 28477143
J Immunol. 2017 Jun 15;198(12):4781-4791
pubmed: 28484052
J Immunol. 2017 Sep 1;199(5):1606-1615
pubmed: 28724580
Cytokine. 2018 Apr;104:78-84
pubmed: 28969945
JCI Insight. 2018 Mar 8;3(5):
pubmed: 29515037
Cell Immunol. 1995 Oct 1;165(1):153-7
pubmed: 7671320

Auteurs

Julie Mouillaux (J)

EA 7426 « Pathophysiology of injury-induced immunosuppression (PI3) » Lyon 1 University / Hospices Civils de Lyon / bioMérieux, Hôpital Edouard Herriot 5 place d'Arsonval, 69003, Lyon, France.
Joint Research Unit HCL-bioMérieux-Université Lyon 1, Hôpital Edouard Herriot, 5 place d'Arsonval, 69003, Lyon, France.

Camille Allam (C)

EA 7426 « Pathophysiology of injury-induced immunosuppression (PI3) » Lyon 1 University / Hospices Civils de Lyon / bioMérieux, Hôpital Edouard Herriot 5 place d'Arsonval, 69003, Lyon, France.
Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, 5 place d'Arsonval, 69003, Lyon, France.

Morgane Gossez (M)

EA 7426 « Pathophysiology of injury-induced immunosuppression (PI3) » Lyon 1 University / Hospices Civils de Lyon / bioMérieux, Hôpital Edouard Herriot 5 place d'Arsonval, 69003, Lyon, France.
Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, 5 place d'Arsonval, 69003, Lyon, France.

Thomas Uberti (T)

Anesthesiology and Intensive care department, Hospices Civils de Lyon, Hôpital Edouard Herriot 5 place d'Arsonval, 69003, Lyon, France.

Benjamin Delwarde (B)

Anesthesiology and Intensive care department, Hospices Civils de Lyon, Hôpital Edouard Herriot 5 place d'Arsonval, 69003, Lyon, France.

Jack Hayman (J)

EA 7426 « Pathophysiology of injury-induced immunosuppression (PI3) » Lyon 1 University / Hospices Civils de Lyon / bioMérieux, Hôpital Edouard Herriot 5 place d'Arsonval, 69003, Lyon, France.
Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, 5 place d'Arsonval, 69003, Lyon, France.

Thomas Rimmelé (T)

EA 7426 « Pathophysiology of injury-induced immunosuppression (PI3) » Lyon 1 University / Hospices Civils de Lyon / bioMérieux, Hôpital Edouard Herriot 5 place d'Arsonval, 69003, Lyon, France.
Anesthesiology and Intensive care department, Hospices Civils de Lyon, Hôpital Edouard Herriot 5 place d'Arsonval, 69003, Lyon, France.

Julien Textoris (J)

EA 7426 « Pathophysiology of injury-induced immunosuppression (PI3) » Lyon 1 University / Hospices Civils de Lyon / bioMérieux, Hôpital Edouard Herriot 5 place d'Arsonval, 69003, Lyon, France.
Joint Research Unit HCL-bioMérieux-Université Lyon 1, Hôpital Edouard Herriot, 5 place d'Arsonval, 69003, Lyon, France.
Anesthesiology and Intensive care department, Hospices Civils de Lyon, Hôpital Edouard Herriot 5 place d'Arsonval, 69003, Lyon, France.

Guillaume Monneret (G)

EA 7426 « Pathophysiology of injury-induced immunosuppression (PI3) » Lyon 1 University / Hospices Civils de Lyon / bioMérieux, Hôpital Edouard Herriot 5 place d'Arsonval, 69003, Lyon, France.
Joint Research Unit HCL-bioMérieux-Université Lyon 1, Hôpital Edouard Herriot, 5 place d'Arsonval, 69003, Lyon, France.
Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, 5 place d'Arsonval, 69003, Lyon, France.

Estelle Peronnet (E)

EA 7426 « Pathophysiology of injury-induced immunosuppression (PI3) » Lyon 1 University / Hospices Civils de Lyon / bioMérieux, Hôpital Edouard Herriot 5 place d'Arsonval, 69003, Lyon, France.
Joint Research Unit HCL-bioMérieux-Université Lyon 1, Hôpital Edouard Herriot, 5 place d'Arsonval, 69003, Lyon, France.

Fabienne Venet (F)

EA 7426 « Pathophysiology of injury-induced immunosuppression (PI3) » Lyon 1 University / Hospices Civils de Lyon / bioMérieux, Hôpital Edouard Herriot 5 place d'Arsonval, 69003, Lyon, France. fabienne.venet@chu-lyon.fr.
Joint Research Unit HCL-bioMérieux-Université Lyon 1, Hôpital Edouard Herriot, 5 place d'Arsonval, 69003, Lyon, France. fabienne.venet@chu-lyon.fr.
Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, 5 place d'Arsonval, 69003, Lyon, France. fabienne.venet@chu-lyon.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH